Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GEMP

Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

Gemphire Therapeutics logo

About Gemphire Therapeutics Stock (NASDAQ:GEMP)

Key Stats

Today's Range
$2.41
$2.84
50-Day Range
$0.30
$6.38
52-Week Range
$0.24
$1.49
Volume
55,454 shs
Average Volume
127,174 shs
Market Capitalization
$37.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Receive GEMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GEMP Stock News Headlines

Bill Gates’s Next Big AI Bet: Stargate
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.
See More Headlines

GEMP Stock Analysis - Frequently Asked Questions

Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15.

Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemphire Therapeutics investors own include TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Pixelworks (PXLW), Clearside Biomedical (CLSD), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Melinta Therapeutics (MLNT).

Company Calendar

Last Earnings
3/15/2019
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GEMP
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
$-23,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.54 per share

Miscellaneous

Free Float
N/A
Market Cap
$39.71 million
Optionable
Not Optionable
Beta
2.82
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:GEMP) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners